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Table
Fatty acid transport, oxidation, andmitochondrial biogenesis in GVHD Tcells
Parameter Naïve* GVHD P value
Fatty Acid Transport
Slc27a2 mRNA 1.0  0.8 42.0  6.7 1.0 >1.0
Transport (% cells
BoDipyHi)y
0.7  0.05 44.3  6.9 0.003
Fatty Acid Oxidation
CPT2 enzyme ratio 1.0  1.7 103  31 0.005
Oxidation (cpm x10-5)z 1.1  0.2 1.9  0.3 0.02
Mitochondrial Biogenesis
Mitochondrial Massx 47.6  14.2 66.3  5.9 0.04
Mitochondrial/nuclear
DNA
1.0  0.07 2.7  0.52 < 0.0001
PGC-1a ratio 1.0  1.3 3900  1200 0.005
* Naïve cells served as controls (values set to 1.0) for mRNA levels and all
ratios
y Uptake of BoDipyC1-C12, a fatty acid analog, was measured by ﬂow
cytometry
z Oxidation measured by the conversion of 3H-palmitate to 3H20,
expressed as cpm of 3H2O
x Mitochondrial mass measured as the % of cells Mitotracker GreenHi
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compared to resting (naïve) T cells (see Table). Donor T cells
also increased levels of enzymes necessary for FA oxidation
(e.g. CPT2) 100-fold and oxidized more FAs. Mitochondrial
mass (required for FA oxidation) increased in donor T cells, as
did the ratio of mitochondrial to nuclear DNA, and the
expression of PGC-1a, a key regulator of mitochondrial
biogenesis. Importantly, T cells proliferating during routine
immune reconstitution (following syngeneic BMT) mini-
mally increased FA transport (10% vs. 40% in GVHD T cells).
Finally, inhibition of FA oxidation in vivo, through irreversible
blockade of CPT1 with etomoxir, decreased the total number
of well-divided donor Tcells after a single dose. Furthermore,
two weeks of etomoxir treatment, beginning on day +7,
improved both GVHD clinical score (1.1 vs. 3.8 in untreated
animals, P ¼ .02) and weight loss at day 40. In total, these
data demonstrate that GVHD T cells up-regulate FA metab-
olism in vivo and that proliferating, donor cells can be
selectively eliminated through inhibition of FA oxidation. Our
data provide novel insights into the metabolism of lympho-
cytes activated in vivo and show that inhibition of FA
oxidationmay be a therapeutic target for the prevention and/
or treatment of GVHD.
422
Biopsies Are Essential During Monitoring of Response to
Mesenchymal Stromal Cell Therapy in Children with
Gastrointestinal Acute Graft Versus Host Disease
Friso Calkoen 1, Els Jol-van der Zijde 1, Astrid van Halteren 1,
Joachim Schweizer 2, Luisa Mearin 2, R. Maarten Egeler 1,3,
Maarten van Tol 1, Lynne Ball 1. 1 Pediatric stem cell
transplantation Unit, Leiden University Medical Center,
Netherlands; 2 Pediatric gastro-enterology, Leiden University
Medical Center, Netherlands; 3 Stem Cell Transplantation,
Hospital for Sick Children, Toronto, ON, Canada
Acute graft-versus-host disease (aGvHD) of the gut based
only on clinical symptoms may be difﬁcult to distinguish
from other causes. Assessing response to treatment may be
hampered by persistent diarrhea resulting from damage to
the gut in the absence of ongoing aGvHD. Histological
examination of gut biopsies conﬁrm the diagnosis but are
invasive. We aimed to determine the importance of biopsies
to evaluate the response to treatment with mesenchymal
stromal cells (MSC) and assess the usefulness of biomarkers.In this study, 18 patients received MSC for severe steroid
refractory aGvHD of the gut (conﬁrmed by a biopsy in 16
patients). In 89% (n¼16) diarrhea persisted after the ﬁrst MSC
and a second (and in 3 cases a third) MSC infusion was
considered. A second gut biopsy was taken from 9 patients
before subsequent MSC infusion and in 6 of these biopsies
(67%) no signs of aGvHD were seen. The 3 patients with
biopsy conﬁrmed active aGvHD showed a response after
a subsequent MSC infusion. Nine out of 18 patients showed
a complete (CR), 4 a partial response (PR) and 5 no response
(NR) at 28 days after starting MSC therapy (1-3 infusions).
Our data suggests that without biopsy evaluation after MSC
infusion, the response to treatment may be underestimated
and over treatment occurs. In contrast patients with a posi-
tive biopsy may beneﬁt from additional MSC treatment.
However, a biopsy of children with aGvHD is not always
feasible. Therefore, the value of previously reported
biomarkers was assessed in our patient cohort (sIL2Ra,
sCK18F, sTNFR1). Patient samples were longitudinally
measured starting before SCT until 50 days after the last MSC
infusion. At the start of aGvHD, serum concentrations of sIL-
2Ra, sTNFR1 and soluble cytokeratin 18 fragment (sCK18F)
were signiﬁcantly elevated compared with samples before
onset. The response at day 28 can be predicted using sIL-2Ra
concentrations on day 7. Patients with CR/PR (n¼13) have
lower sIL-2Ra concentrations compared to non-responders
(n¼5) (P ¼ .015). The value of REG-3a in predicting the
occurrence of gut aGvHD and monitoring the effect of
treatment is currently being investigated.
In our opinion biomarkers can contribute to the diagnostic
process, but biopsy remains the golden standard for the
diagnosis and short term response to treatment of aGvHD.
Sequential biopsies should be included in randomized
controlled trials to validate the importance of biomarkers in
monitoring response to experimental cellular therapy.423
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We previously reported that the maximum tolerated dose
(MTD) of NLT for cGvHD was 200 mg daily for 16 subjects
treated according to a standard 3+3 dose escalation schema
(Chen et al, Blood 2011 118: Abstract 1986). We present new
efﬁcacy data and update prior safety and pharmacokinetic
data in 28 subjects.
Methods: All subjects had extensive steroid dependent/
refractory cGvHD previously treated with  2 agents.
Glucocorticoid (GC) refractory was deﬁned as progressive
cGVHD despite prednisone  0.5 mg/kg/d for  1 month;
steroid dependence was cGvHD requiring prednisone 0.25
mg/kg/d for  3 months. GCs and two other immunosup-
pressants were allowed. Prior imatinib use was allowed. GCs
were tapered as tolerated and other immunosuppressant
dosing remained constant. Safety was determined by
observation of CTCAE v. 4.0 graded adverse events (AEs).
Trough plasma NLT concentrations were determined by LC/
MS before the daytime day 8 dose. Clinical activity of NLTwas
indicated by change in NIH composite skin (D 1) and Lee
symptom skin scores (improvement D 13, worsening D
-20).
Results: Median (range) follow-up was 153 (19-581) days.
Median age (range) was 50.3 (24.5-76.4) years. Mean time
(range) to study enrollment from transplant was 3.8 (1.5-
13.3) years and from cGvHD diagnosis 3.4 (0.3-12.6) years.
The Table shows grade 2-3 AEs possibly or probably attrib-
uted to NLT. So far no grade 4-5 AEs attributed to NLT have
occurred. Median trough concentration of NLT 1 week after
drug initiation at the MTD (n¼23) was 761 nM (range 120-
2290 nM). 26 subjects were evaluable for response. 6 remain
on drug. 20 were removed from the study for progressive
disease (7), toxicity (7), withdrawal of consent (5), and
progression of underlying malignancy (1). Skin disease
responses could be evaluated in 19 subjects. NIH composite
skin score was improved in 4, unchanged in 14, and wors-
ened in 1. Lee symptom skin score was improved in 6 and
unchanged in 13. Among the 7 subjects with progressive
cGvHD, NIH composite or Lee symptom skin score was
unchanged or worsened in 5, improved in 1, and unevaluable
in 1.
Conclusions: Skin improvement in some patients suggests
that NLT 200 mg daily may have clinical activity. Median
trough concentrations that exceeded the IC50s for PDGFRA,
DDR1, DDR2, ABL, and KIT but not NQO2 support this. 200mg
daily, however, is associated with signiﬁcant toxicity. LowerAdverse Event Grade 2
(n¼28)
Grade 3
(n¼28)
Arterial injury 1
Decreased joint ﬂexion 1 1
Dehydration 1
LFT elevation 2 1
Hyponatremia 1
Hypophosphatemia (1 V) 6 3
Increased lipase (3 V) 2 2
Inﬂuenza B 1
Muscle cramping 1 1
Neutropenia (afebrile) 1 1
Pneumocystis carinii pneumonia (1 V) 1
Prolonged QTc 1
Shingles 1 1
Suspected fungal pneumonia 1
URI 1
Worsening Fatigue 2
V DLTdaily doses or alternate day dosing may continue to generate
disease responses while improving tolerability and should be
explored.
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Background: Based on our clinical impression, pts with
grade 3-4 aGVHD have had improved survival in recent years.
In order to explore this observed trend, we evaluated factors
associated with outcome in these pts.
Methods: Pts who had an allogeneic stem cell transplant
(SCT) and who were evaluable for aGVHD by Glucksberg
criteria were included, with SCT segregated into the
following time periods (pds): 1990-1994, 1995-1999, 2000-
2004, and 2005-2011. Pts undergoing cord or haplo-identical
SCT were excluded. We evaluated the impact of variables of
interest and time pd of SCT on overall survival (OS), deﬁned
as time from SCT to death, using univariate and multivariate
analyses.
Results: 959 pts were included (See Table), and 62.5% had
peripheral blood (PB) grafts. Of the 388 unrelated SCT's, 56%
received anti-thymocyte globulin (ATG). Thirty-seven
percent of all pts had reduced-intensity conditioning, and
91% were complete HLA matches. Median recipient age was
47 years (range: 18 e 75), but age increased with time pd of
SCT (See Table; P< .0001). Use of a male donor also increased
with time (P< .0001). Grade 3-4 aGVHD incidence was 16.6%
and signiﬁcantly differed by time pd (See Table;P ¼ .028). It
occurred in 17.6% of pts receiving ATG, compared to 28.7% of
those who did not receive ATG (P ¼ .005). After including
time pd and other donor- and graft-related covariates, only
ATG administration was a signiﬁcant predictor for decreased
grade 3-4 aGVHD (P ¼ .026). Use of PB graft approached
signiﬁcance (P¼ .053). 568 pts have died, andmedian follow-
up is 49 months (range: 3 to 253) in living pts. Median OS for
pts with grade 3-4 aGVHD is 5.0 months, compared to 36.2
and 34.8 months for pts with grade 2 and grade 0-1 aGVHD,
respectively (P < .0001). Among pts with grade 3-4 aGVHD,
median OS is improved with more recent SCT (See Table;P ¼
.018). Having a male donor (P ¼ .0018) and a PB graft (0.017)
are also associated with improved OS in univariate analyses,Table
1990-
1994
1995-
1999
2000-
2004
2005-
2011
All
periods
# of Patients 122 173 207 457 959
Median Age 35 43 46 52 47
Percent male
donors
57 52 57 72 63
Incidence
Grade 3-4
GVHD (%)
18 23.1 17.4 13.3 16.6
Median OS, mo 19.6 25.5 11.0 37.9 22.3
Median OS, mo
(pts with Gr 3-4
GVHD)
3.7 5.7 3.5 8.8 5.0
